ArticleNeurosurgical review2026
Clinical and molecular characteristics of thalamic gliomas in adults: prognostic impact of TERT promoter mutation.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdult thalamic gliomas (ATGs) are rare and biologically heterogeneous tumors. Although the 2021 World Health Organization (WHO) classification designates all diffuse midline gliomas (DMGs), H3-altered, as grade 4, accumulating evidence suggests that adult thalamic DMGs may exhibit more indolent clinical behavior, compared with glioblastomas or pediatric DMGs. In this study, we aimed to characterize the clinical, radiological, pathological, and molecular features of ATGs and identify clinically relevant prognostic markers, with particular focus on H3K27M and TERT promoter (TERTp) mutations.
methodsWe retrospectively analyzed 45 adult patients (≥ 18 years) who underwent surgical resection or biopsy for ATGs between 2007 and 2023. Clinical, radiological, pathological, and molecular data were collected, and prognostic factors for overall survival were evaluated.
resultsPatients with thalamic DMG demonstrated significantly longer overall survival (OS) than those with glioblastoma (median OS, 24.6 vs. 12.4 months; p = 0.035). In multivariate Cox regression analysis adjusted for age, WHO grade, H3K27M status, and TERTp status, TERTp mutation emerged as an independent predictor of poor survival (hazard ratio [HR], 1.81; p = 0.026), whereas H3K27M mutation was not significantly associated with outcome (HR, 0.93; p = 0.77). Younger age (< 45 years) was independently associated with longer OS, and WHO grade 4 with shorter survival; however, the survival curves overlapped substantially across histological grades.
conclusionsIn ATGs, TERTp mutation was an independent predictor of poor survival and provided prognostic information beyond H3K27M status. These findings support incorporating TERTp status into risk stratification for ATGs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.